# S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

> **NCT00064337** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 104 (actual)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** melphalan
- **DRUG:** thalidomide
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00064337
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2012-05
- **Final completion:** 2015-11
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064337, "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00064337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*